🔍

APOLLOHOSP - Apollo Hospitals

📊 NSE: APOLLOHOSP 🏢 Healthcare 📅 Last Updated: 12/13/2025 18:25

📢 Recent Corporate Announcements

Apollo Hospitals Releases Q3 FY26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 14 Feb 2026, 12:24 PM

Apollo Hospitals Enterprise Limited has officially released the transcript of its earnings conference call held on February 11, 2026. The transcript covers the company's unaudited financial performance for the third quarter and the nine-month period ending December 31, 2025. This document provides detailed management commentary and responses to institutional investor queries regarding operational metrics and future strategy. It is a standard regulatory disclosure following the announcement of quarterly results.

Transcript pertains to the earnings call conducted on February 11, 2026.
Covers financial performance for the nine-month period ended December 31, 2025.
Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements.
Provides management insights into hospital segment performance and pharmacy business growth.
The full document is accessible via the company's official investor relations portal.

💡 Investors should review the transcript to understand management's guidance on bed occupancy, ARPOB trends, and the timeline for profitability in the digital health segment.

Apollo Hospitals Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 09:44 AM

Apollo Hospitals Enterprise Limited has officially released the audio recording of its analyst call held for the financial results of Q3 and 9M FY26. The recording covers management's discussion on performance for the period ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure all investors have access to the same information. The link is now available on the company's website for public review.

Audio recording of the Q3 FY26 analyst call is now accessible via the company's website.
The call discussed financial results for the three and nine-month periods ended December 31, 2025.
Disclosure made in compliance with Regulations 30 and 46(2) of SEBI LODR.
Official filing date recorded as February 12, 2026.

💡 Investors should listen to the recording to understand management's commentary on occupancy levels, ARPOB trends, and the growth trajectory of the Apollo 24/7 digital platform. This is a routine update and does not require immediate portfolio changes.

Apollo Hospitals Q3 FY26: Consolidated PAT Surges 170% YoY to ₹5,023 Million

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 06:32 PM

Apollo Hospitals Enterprise Limited reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's bottom line saw a massive jump, with PAT increasing 170% YoY to ₹5,023 million, driven by strong operational performance across all business verticals. The core Healthcare Services segment maintained healthy EBITDA margins of 24.8%, while the Apollo HealthCo and AHLL segments both recorded 20% revenue growth, signaling strong momentum in digital health and retail clinics.

Consolidated Revenue increased by 17% YoY to ₹64,774 million in Q3 FY26.
Consolidated PAT witnessed a significant 170% YoY surge, reaching ₹5,023 million.
Healthcare Services (Hospitals) reported an EBITDA margin of 24.8% with 67% occupancy.
Apollo HealthCo (Digital & Pharmacy) revenue grew 20% YoY to ₹28,274 million with 7,113 outlets.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, reflecting improved profitability.

💡 Investors should take note of the significant margin expansion and the massive jump in PAT, which indicates strong operational efficiency. The continued growth in the digital health platform (Apollo 24|7) and the pharmacy network strengthens the company's long-term competitive position.

Apollo Hospitals Q3 FY26 PAT Surges 170% YoY to ₹4,219 Million

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 10 Feb 2026, 06:27 PM

Apollo Hospitals reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's Profit After Tax (PAT) saw a massive jump of 170% YoY, reaching ₹4,219 million, driven by strong operational efficiencies and growth across all business segments. Healthcare services remained the primary contributor with a 24.8% EBITDA margin, while the digital health and pharmacy segment (HealthCo) continued its growth trajectory with 20% revenue growth.

Consolidated PAT increased by 170% YoY to ₹4,219 million in Q3 FY26.
Healthcare Services revenue grew 14% YoY to ₹31,832 million with an EBITDA margin of 24.8%.
Average Revenue per IP Patient (ARPOB) stood at ₹180,917 with 67% occupancy across 10,325 beds.
Apollo HealthCo (Digital & Pharmacy) revenue rose 20% YoY to ₹28,274 million.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, showing improved profitability in diagnostics and clinics.

💡 The strong growth in PAT and steady margins in the core hospital business make this a positive update for long-term investors. Monitor the continued scaling and path to profitability of the Apollo 24|7 digital platform as it integrates further with the pharmacy business.

Apollo Hospitals Q3 FY26: PAT Surges 170% YoY to ₹5,023 Million; HealthCo Turns Profitable

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 10 Feb 2026, 06:27 PM

Apollo Hospitals Enterprise Limited reported a robust Q3 FY26 with consolidated revenue growing 15% YoY to ₹64,774 million. The company achieved a significant milestone as its Apollo HealthCo segment (Digital & Pharmacy) turned EBITDA positive at ₹1,279 million, compared to a loss of ₹1,027 million in the previous year. Net profit (PAT) saw a massive 170% jump to ₹5,023 million, driven by strong hospital margins and the digital turnaround. The core Healthcare Services division maintained a healthy 24.8% EBITDA margin with an average revenue per inpatient of ₹180,917.

Consolidated Revenue increased 15% YoY to ₹64,774 million in Q3 FY26.
Net Profit (PAT) grew by 170% YoY to ₹5,023 million.
Apollo HealthCo achieved EBITDA of ₹1,279 million, a sharp recovery from a ₹1,027 million loss in Q3 FY25.
Healthcare Services (Hospitals) reported 14% revenue growth and 18% EBITDA growth with 67% occupancy.
Pharmacy network expanded to 7,113 outlets with 46 million registered users on the Apollo 24|7 platform.

💡 The turnaround in the digital health and pharmacy segment is a major positive trigger for the stock's valuation. Investors should maintain a positive outlook given the strong hospital margins and the scaling of the omni-channel healthcare platform.

Apollo Hospitals Subsidiary Acquires Belenus Champion Hospitals for Rs 1,650 Million

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Feb 2026, 06:23 PM

Apollo Hospitals' subsidiary, Imperial Hospital and Research Centre Limited, has completed the 100% acquisition of Belenus Champion Hospitals in Bangalore for a total cost of Rs 1,650 million. The target company, which operates a 125-bed facility, reported a turnover of Rs 274.90 million in FY25. Apollo plans to invest a total of Rs 3,000 million to upgrade and expand the facility to 175 beds. The revamped multi-speciality hospital is scheduled to reopen by Q1 FY27, strengthening Apollo's footprint in the Bangalore healthcare market.

Acquired 100% stake in Belenus Champion Hospitals for a total consideration of Rs 1,650 million including liabilities.
Target company reported FY25 revenue of Rs 274.90 million compared to Rs 305.84 million in FY24.
Total project cost of Rs 3,000 million earmarked for acquisition and expansion to a 175-bed facility.
The hospital is currently being upgraded and is expected to be operational by Q1 FY27.
Acquisition executed through a 90% owned subsidiary, making Belenus a step-down subsidiary of Apollo Hospitals.

💡 Investors should monitor the progress of the facility upgrade as this acquisition strengthens Apollo's presence in the high-demand Bangalore market. The long-term value will depend on the successful turnaround and scaling of the 175-bed facility by FY27.

Apollo Hospitals Q3FY26 Standalone PAT up 12% YoY to ₹384 Cr; Declares ₹10 Interim Dividend

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 10 Feb 2026, 06:11 PM

Apollo Hospitals reported a robust performance for Q3FY26 with standalone revenue growing 15% YoY to ₹2,364 crore. Standalone EBITDA increased by 16% YoY to ₹594 crore, while Profit After Tax rose 12% to ₹384 crore, despite a one-time exceptional charge of ₹11.4 crore related to new labour codes. The Board has declared an interim dividend of ₹10 per share (200% of face value) with a record date of February 16, 2026. The company is also progressing with its strategic restructuring to demerge its pharmacy and digital health businesses.

Standalone Revenue from operations grew 15% YoY to ₹23,637 million compared to ₹20,548 million in Q3FY25.
Standalone EBITDA rose 16% YoY to ₹5,935 million from ₹5,118 million in the previous year.
Interim dividend of ₹10 per share declared; Record date fixed as February 16, 2026.
Profit After Tax (PAT) increased 12.3% YoY to ₹3,835 million despite an exceptional cost of ₹114 million.
Company has filed an application with NCLT for the demerger of its pharmacy distribution and digital health platform.

💡 Investors should take note of the steady double-digit growth across key financial metrics and the healthy dividend payout. The upcoming demerger of the pharmacy and digital health business remains a key monitorable for long-term value unlocking.

Apollo Hospitals Declares ₹10 Interim Dividend; Q3 PAT Rises 12% YoY to ₹3,835 Million

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 10 Feb 2026, 06:03 PM

Apollo Hospitals has declared an interim dividend of ₹10 per share (200% of face value) for FY26, with the record date fixed for February 16, 2026. The company reported a 15% YoY growth in standalone revenue to ₹23,637 million for the quarter ended December 31, 2025. Standalone Profit After Tax (PAT) grew by 12% YoY to ₹3,835 million, even after accounting for a ₹114 million exceptional charge related to new labour codes. Additionally, the company is progressing with its composite scheme of arrangement for the demerger of its pharmacy and digital health businesses, currently awaiting NCLT approval.

Interim dividend of ₹10 per share (200% of FV) declared with a record date of February 16, 2026.
Standalone Revenue from operations increased 15% YoY to ₹23,637 million in Q3 FY26.
EBITDA grew 16% YoY to ₹5,935 million, maintaining healthy operational margins.
Net Profit (PAT) for the quarter stood at ₹3,835 million compared to ₹3,416 million in the previous year.
Exceptional item of ₹114 million recorded due to regulatory changes in Labour Codes affecting employee benefits.

💡 Investors seeking dividend income should ensure they hold the stock before the February 16 record date. Long-term investors should track the NCLT approval process for the pharmacy business demerger as it could unlock significant value.

Apollo Hospitals Q3 PAT Rises 12% to ₹383.5 Cr; Declares ₹10 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 05:50 PM

Apollo Hospitals Enterprise Limited reported a steady performance for Q3 FY26, with standalone revenue from operations growing 15% YoY to ₹2,363.7 crore. Net profit increased by 12.3% YoY to ₹383.5 crore, despite a one-time exceptional charge of ₹11.4 crore due to new labour code provisions. The company rewarded shareholders with an interim dividend of ₹10 per share. Furthermore, the company has moved forward with its restructuring plan, filing an application with the NCLT for the demerger of its pharmacy and digital health businesses.

Standalone Revenue from operations increased 15% YoY to ₹2,363.7 crore from ₹2,054.8 crore.
EBITDA grew by 16% YoY to ₹593.5 crore compared to ₹511.8 crore in the same quarter last year.
Profit After Tax (PAT) stood at ₹383.5 crore, up from ₹341.6 crore in Q3 FY25.
Declared an interim dividend of ₹10 per share (200% of face value) with a record date of Feb 16, 2026.
Exceptional item of ₹11.4 crore recognized due to increased gratuity and leave liabilities under new Labour Codes.

💡 Investors should maintain a positive outlook given the consistent growth in the core healthcare segment and the upcoming value unlocking from the pharmacy business demerger. The interim dividend provides an immediate yield benefit while waiting for the restructuring to conclude.

Apollo Hospitals to Host Q3 FY26 Earnings Call on February 11, 2026

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 30 Jan 2026, 10:50 AM

Apollo Hospitals Enterprise Limited (AHEL) has scheduled its Q3 FY26 earnings conference call for February 11, 2026, at 2:00 PM IST. This follows the official announcement of the financial results for the quarter and nine months ended December 31, 2025, which is slated for February 10, 2026. The call will be led by top management, including Managing Director Suneeta Reddy and the CEOs of the Hospitals and HealthCo divisions. Investors will be looking for updates on the performance of the company's 10,000+ beds and its expanding pharmacy and digital health network.

Financial results for Q3 FY26 to be announced on Tuesday, February 10, 2026
Earnings conference call scheduled for Wednesday, February 11, 2026, at 2:00 PM IST
Management team including MD Suneeta Reddy and Group CFO A. Krishnan will participate
Discussion will cover operations across 73 hospitals and over 6,000 pharmacies

💡 Investors should mark the result date of February 10 and monitor the subsequent conference call for management's outlook on hospital occupancy and HealthCo's path to profitability.

CRISIL Revises Apollo Hospitals' Outlook to 'Positive'; Reaffirms 'AA+' Rating

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 27 Jan 2026, 06:18 PM

CRISIL Ratings has revised the outlook on Apollo Hospitals Enterprise Ltd (AHEL) to 'Positive' from 'Stable' while reaffirming its 'CRISIL AA+' rating. This revision reflects AHEL's dominant market position as India's largest private healthcare provider and expectations of sustained mid-teen revenue growth. The company is projected to achieve consolidated revenues of over Rs. 24,000 crores in fiscal 2026 with healthy EBITDA margins of 23-24% post-demerger of its pharmacy business. Despite a planned capex of Rs. 6,000 crore for bed expansion, the company maintains a robust financial profile with a cash surplus of Rs. 3,222 crore.

Long-term rating outlook revised to 'Positive' from 'Stable'; 'CRISIL AA+' rating reaffirmed.
Consolidated revenue estimated to grow 12-15% YoY to over Rs. 24,000 crores in fiscal 2026.
Planned capex of ~Rs. 6,000 crore to add 3,600+ beds over the next 3-5 years.
Strong liquidity position with cash and cash equivalents of Rs. 3,222 crore as of September 30, 2025.
Debt/EBITDA estimated at 1.65x for FY26, with expectations to drop below 1.5x by FY27.

💡 The outlook revision to 'Positive' indicates a potential rating upgrade in the medium term, reflecting strong operational cash flows and market leadership. Investors should view this as a sign of high credit quality and financial stability as the company executes its massive bed expansion plan.

Apollo Hospitals gets CCI nod to acquire 30.58% stake in AHLL for Rs 12,540.68 million

🟢 POSITIVE ⭐ 8/10

M&A 📅 21 Jan 2026, 04:24 PM

Apollo Hospitals Enterprise Limited has received approval from the Competition Commission of India (CCI) to acquire a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The acquisition involves purchasing 41,650,368 equity shares from the International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. This move consolidates Apollo's ownership in its retail healthcare arm, which includes clinics, diagnostics, and primary care. The transaction follows the initial board approval granted in September 2025.

CCI approved the acquisition of 41,650,368 equity shares (30.58% stake) in AHLL.
The total purchase consideration for the stake is Rs 12,540.68 million.
The stake is being acquired from International Finance Corporation (IFC) and IFC EAF Apollo Investment Company.
This acquisition increases Apollo's control over its high-growth retail healthcare and diagnostics business.

💡 Investors should view this consolidation of a key subsidiary as a positive long-term move for earnings accretion. Monitor the impact on the company's cash flow and the subsequent growth trajectory of the AHLL segment.

Apollo Hospitals gets CCI nod to acquire 30.58% stake in AHLL for ₹1,254 crore

🟢 POSITIVE ⭐ 8/10

M&A 📅 21 Jan 2026, 04:10 PM

Apollo Hospitals Enterprise Limited has received approval from the Competition Commission of India (CCI) to acquire a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The company will purchase 41,650,368 equity shares from the International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. This acquisition, originally approved by the board in September 2025, consolidates Apollo's ownership in its retail healthcare and diagnostics arm. The regulatory clearance marks a significant milestone in completing this strategic transaction.

CCI approved the acquisition of 41,650,368 equity shares in subsidiary AHLL.
The 30.58% stake is being acquired for a total purchase consideration of Rs 12,540.68 million.
The stake was jointly held by International Finance Corporation (IFC) and IFC EAF Apollo Investment Company.
The acquisition follows the board's prior approval granted on September 12, 2025.
Consolidates ownership in the high-growth retail healthcare and lifestyle business segment.

💡 Investors should view this consolidation of ownership in a key subsidiary as a positive move for long-term value creation. Monitor the impact on consolidated earnings as the company gains full control over AHLL's cash flows.

Apollo Hospitals Files Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Jan 2026, 12:14 PM

Apollo Hospitals Enterprise Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that all share certificates received for dematerialization during the quarter ended December 31, 2025, were processed and confirmed to the depositories. The company verified that physical certificates were mutilated and cancelled as per regulatory requirements. This is a standard administrative procedure to ensure the integrity of electronic shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Confirms that securities received for dematerialization were processed within the stipulated time limit.
Physical share certificates were mutilated and cancelled after due verification by depository participants.
Register of members updated to reflect depositories as the registered owners for dematerialized shares.

💡 This is a routine regulatory filing with no impact on the company's financial performance or stock valuation; no action is required from investors.

Apollo Hospitals to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 12:29 PM

Apollo Hospitals Enterprise Limited has announced the closure of its trading window effective from January 1, 2026. This closure is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations for the consideration of unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all directors, designated employees, and insiders until 48 hours after the financial results are officially declared. The specific date for the Board Meeting to approve these results will be communicated at a later time.

Trading window closure commences on Thursday, January 1, 2026.
Closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025.
The window will reopen 48 hours after the results are announced to the stock exchanges.
Restriction applies to all directors, designated employees, and their immediate relatives.

💡 This is a routine administrative announcement with no impact on the company's fundamentals. Investors should monitor for the upcoming board meeting date to prepare for the Q3 FY26 financial performance results.

View All APOLLOHOSP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 15% YoY in FY25. Healthcare services segment, back-end pharmacy (AHL), and diagnostics/retail health were primary drivers. Pharmacy distribution grew 16% YoY. In Q2 FY26, Apollo HealthCo revenue reached INR 2,661 Cr (up 17% YoY) and Apollo Health & Lifestyle (AHLL) reached INR 474 Cr (up 17% YoY).

Geographic Revenue Split

Revenue is diversified across India: Tamil Nadu contributes 25%, Andhra Pradesh and Telangana 16%, and the Eastern region 23%. The remaining is spread across other geographies and metro/tier-2 cities.

Profitability Margins

Consolidated operating margins improved by 120 bps to 13.9% in FY25 from 12.7% in FY24. Healthcare services maintain robust margins of over 24%. Apollo HealthCo (AHL) margins improved to 1.8% in FY25 from negative levels in FY23/24. Post-demerger of AHL in FY28, margins are expected to reach 21-24%.

EBITDA Margin

Consolidated EBITDA margin is expected to sustain at 13.5-14% in FY26. Healthcare segment EBITDA is strong at 24%. Apollo HealthCo reported an EBITDA of INR 110 Cr in Q2 FY26, up 111.5% from INR 52 Cr in Q2 FY25.

Capital Expenditure

In FY25, total capital expenditure was INR 1,712.7 Cr, comprising INR 1,415.2 Cr for Hospitals, INR 143.7 Cr for AHLL, and INR 153.8 Cr for HealthCo. Planned expansion includes adding 3,500-4,300 beds over the next 3-4 years.

Credit Rating & Borrowing

Maintained 'CRISIL AA+/Stable/CRISIL A1+' rating. Total debt (including lease liabilities) stood at INR 5,389 Cr as of March 2025. The company availed new debt of INR 2,585.3 Cr in FY25 with a gearing ratio of 0.61x.

⚙️ Operational Drivers

Raw Materials

Material costs (medicines, surgical consumables, and medical supplies) represent 25.3% of total revenue.

Key Suppliers

Keimed Pvt Ltd is a key partner for pharmacy distribution infrastructure; other medical equipment and pharmaceutical vendors are used with renegotiated rates to improve unit economics.

Capacity Expansion

Current network includes 6,626 retail pharmacy stores. Planned expansion of 15 hospitals with a combined capacity of 4,300 beds in new and existing markets. Pharmacy segment aims to add at least 500 stores annually.

Raw Material Costs

Material costs are maintained at 25.3% of revenue, moving in line with revenue growth. Procurement strategies include leveraging Keimed's infrastructure and renegotiating vendor rates to reduce digital vertical losses by INR 30 Cr YoY in Q2 FY26.

Manufacturing Efficiency

Occupancy levels improved to 68% in FY25 from 65% in FY24. Average Revenue Per Occupied Bed (ARPOB) grew 5% YoY to INR 60,588. Inpatient (IP) discharges grew 7% to 604,250.

Logistics & Distribution

Pharmacy distribution business leverages a network of 6,626 stores and 96 distribution centers to ensure pan-India accessibility.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be achieved through the addition of 3,500-4,300 beds over 4 years, adding 500 pharmacy stores annually, and scaling the Apollo 24/7 digital platform (currently 44 million users). The company is also focusing on high-end surgical volumes in Centres of Excellence and increasing the mix of private label pharmacy products (currently 15.2% of revenue).

Products & Services

Inpatient and outpatient healthcare services, surgical procedures, pharmacy retail and distribution, diagnostic tests, and digital healthcare consultations via Apollo 24/7.

Brand Portfolio

Apollo Hospitals, Apollo 24/7, Apollo HealthCo, Apollo Health & Lifestyle (AHLL), Keimed, Apollo ESOP 2024.

New Products/Services

Expansion of private labels and generics in pharmacy (15.2% of revenue), digital therapeutics, and insurance monetization through the Apollo 24/7 platform.

Market Expansion

Expansion into Metro Tier 1 and Tier 2 cities with 15 new hospitals. Pharmacy expansion targeting 1,100+ cities and towns.

Market Share & Ranking

Largest private healthcare provider in the domestic Indian market; pharmacy business is more than 2x the size of the nearest competitor.

Strategic Alliances

Strategic investment of INR 725 Cr in Keimed Pvt Ltd by Apollo HealthCo to strengthen the distribution supply chain.

🌍 External Factors

Industry Trends

The industry is shifting toward omnichannel healthcare and digital integration. Apollo is positioning itself as a leader through Apollo 24/7, aiming for breakeven in the digital vertical within 6 quarters.

Competitive Landscape

Operates in a highly competitive market with other private hospital chains and unorganized retail pharmacies, but maintains leadership through scale and clinical excellence.

Competitive Moat

Durable moat through brand equity, the largest physical hospital network in India, JCI accreditations, and a pharmacy business with 2x the scale of competitors. Sustainability is high due to high switching costs in specialized tertiary care.

Macro Economic Sensitivity

Sensitive to domestic economic growth and healthcare spending; however, the essential nature of healthcare provides some resilience to inflation.

Consumer Behavior

Increasing preference for digital health services and home delivery of medicines, addressed by the 44 million user base on Apollo 24/7.

Geopolitical Risks

Minimal direct impact as operations are primarily domestic (India), though global supply chains for medical equipment may be affected.

⚖️ Regulatory & Governance

Industry Regulations

Subject to healthcare regulations, pollution norms for medical waste, and potential government pricing controls on essential medicines and medical procedures.

Environmental Compliance

The company ensures responsible disposal of medical waste and adheres to safety and skills upgradation training for all employees.

Taxation Policy Impact

Deferred tax liability stood at INR 458 Cr in FY25; no significant change from previous year.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the continued cash burn of the Apollo 24/7 platform, which is expected to incur INR 350-400 Cr in annual spends over the medium term.

Geographic Concentration Risk

High concentration in South India, with Tamil Nadu, Andhra Pradesh, and Telangana accounting for 41% of the hospital footprint.

Third Party Dependencies

Significant dependency on Keimed for the back-end pharmacy supply chain and distribution.

Technology Obsolescence Risk

Risk of digital platform obsolescence; mitigated by continuous investment in Apollo 24/7 and recruitment of specialized medical consultants for advanced procedures.

Credit & Counterparty Risk

Receivables increased in FY25, contributing to a higher current ratio, but liquidity remains robust with over INR 1,900 Cr steady-state cash expected.